Gibbons R P, Scott W W, Johnson D E, Prout G R, Schmidt J D, Murphy G P
Urology. 1976 Sep;8(3):222-6. doi: 10.1016/0090-4295(76)90371-x.
This National Cooperative Study has randomly compared the usefulness of 5-fluorouracil (5-FU), cyclophosphamide (Cytoxan) and standard therapy in patients with advanced carcinoma of the prostate (Stage D). All patients studied were endocrine failures and were in progression. Favorable responses were seen with all three treatments regardless of histologic grade. Actual tumor regression occurred only in patients who received either 5-FU or cyclophosphamide. In patients with poorly differentiated or anaplastic tumors treated with cyclophosphamide, progression of disease was significantly less rapid than in patients treated with 5-FU or standard therapy. However, favorable responders could not always be identified in advance on the basis of histologic grade alone.
这项全国性合作研究对5-氟尿嘧啶（5-FU）、环磷酰胺（癌得星）及标准疗法在晚期前列腺癌（D期）患者中的有效性进行了随机比较。所有研究患者均为内分泌治疗无效且病情处于进展期。无论组织学分级如何，三种治疗方法均观察到了良好的反应。实际的肿瘤消退仅发生在接受5-FU或环磷酰胺治疗的患者中。在用环磷酰胺治疗的低分化或间变性肿瘤患者中，疾病进展明显比接受5-FU或标准疗法的患者缓慢。然而，仅根据组织学分级并不能总是提前识别出良好的反应者。
